Avacta Group Plc

Equities

Market Closed - London S.E. Other stock markets 09:05:00 08/05/2026 pm IST			5-day change	1st Jan Change
82.50 ^GBX	+1.85%		+10.00%	+42.24%

06/05	Avacta Therapeutics Presents New Comparisons Of Pre\|CISION Payload Release Versus Approved ADCs And AVA6207 Dual Payload Delivery	CI
22/04	Vaalco says remainder of 2026 to be "very profitable"	AN

Published on 06/06/2025 at 11:35 pm IST - Modified on 06/07/2025 at 02:20 am IST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good morning, and welcome to the Avacta Group Plc Investor Presentation. [Operator Instructions] Due to the high attendance on today's call, the

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

06/05	Avacta Therapeutics Presents New Comparisons Of Pre\|CISION Payload Release Versus Approved ADCs And AVA6207 Dual Payload Delivery	CI
22/04	Vaalco says remainder of 2026 to be "very profitable"	AN
21/04	Avacta Therapeutics Presents Favorable Data for AVA6103 and Showcases Dual Payload pre\|CISION Platform At AACR 2026	CI
10/04	Somero Enterprises extends buyback to USD6.0 million	AN
09/04	Avacta hails "important milestones" in start of "transformative" year	AN
31/03	Avacta Therapeutics Announces First Patient Treated In Phase 1 Focus-01 Trial Of FAP-Exd	CI
27/03	Avacta Therapeutics Conditionally Raises GBP10 Million via Share Placing, Subscription	MT
27/03	Avacta raises GBP10 million in equity for clinical tests	AN
27/03	Avacta Therapeutics says placing & subscription represent 3.60% of issued share capital	RE
27/03	Avacta to Raise GBP10 Million via Equity Placing, Subscription	MT
26/03	Avacta Therapeutics proposed placing via accelerated bookbuild & subscription to raise about £10 million	RE
16/03	Avacta opens phase 1 trial for conjugate's efficacy regarding tumours	AN
16/03	Avacta Group announces phase 1 study opening for AVA6103	RE
24/02	Avacta hails new data supporting proprietary preCision platform	AN
24/02	Avacta Therapeutics Plans FAP-Exd's Clinical Trials After 'Favorable' Experimental Analysis	MT